Our Products


48-49 Russell Square, London, WC1B 4JP UK

T: +44 (0)203 0084416

E: info@valirx.com

Our Products

VAL101 is a novel therapeutic based on the Company’s proprietary GeneICE (Gene Inactivation by chromatin engineering) platform, which attracted a €1.2 million Eurostars grant to fund its development. It acts to target and switch “OFF” the gene that expresses Bcl-2, a protein that is implicated in about half of all carcinomas. Bcl-2 inhibits the critical process of apoptosis (programmed cell death), which prevents cancer development. Thus, because of its function in anti-apoptosis, the Bcl-2 gene has become a major target in the development of new, superior anticancer therapies. Pre-clinical studies have established VAL101’s efficacy in prostate, ovarian and pancreatic cancers, and may also have anti-tumour activity against orphan oncologic indications.

VAL201 is a novel peptide for the treatment of hormone refractory prostate cancer and also other indications of hormone induced unregulated growth including endometriosis. These conditions have major unmet clinical needs and the personalised approach provided by VAL201 promises to significantly improve treatment outcomes. Pre-clinical studies conducted in collaboration with Oxford University have also established that this compound has the potential to reduce side effects as it leaves other hormone-induced activities working normally.